Prosecution Insights
Last updated: July 17, 2026
Application No. 18/293,313

RNAYLATION

Non-Final OA §112
Filed
Jan 29, 2024
Priority
Jul 29, 2021 — EU PCT/EP2021/071295 +1 more
Examiner
LANKFORD JR, LEON B
Art Unit
1657
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
UNIVERSITAT HEIDELBERG
OA Round
1 (Non-Final)
70%
Grant Probability
Favorable
1-2
OA Rounds
1y 3m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 70% — above average
70%
Career Allowance Rate
512 granted / 731 resolved
+10.0% vs TC avg
Strong +31% interview lift
Without
With
+30.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
31 currently pending
Career history
761
Total Applications
across all art units

Statute-Specific Performance

§101
4.4%
-35.6% vs TC avg
§103
60.2%
+20.2% vs TC avg
§102
6.4%
-33.6% vs TC avg
§112
19.7%
-20.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 731 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant's election with traverse of Group I, claims 1-4 and SEQ ID 1 in the reply is acknowledged. The traversal is on the ground(s) that the technical feature of the claims, common across all 3 groups of claims set out on page 3 of the Action, is a fusion protein or complex comprising the claimed tag and a polypeptide of interest. This is not found persuasive for the reasons of record as it is not clear whether the fusion proteins claimed are different than those it the art, however when the clarity issues indicated below are addressed, the lack of unity will be reconsidered. The requirement is still deemed proper and is therefore made FINAL. Claims 1-4 are considered on the merits as they read on the elected species of SEQ ID No 1. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-4 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Applicant uses the claim limitation “preferably comprises or consists of”’ which renders the claims indefinite because the use of the three limitations “preferably,” “consisting,” and “comprising” is a combination of an phrase the renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention (MPEP § 2173) and transitional phrases which are in opposition to each others making it unclear what the intended scope of applicant’s invention is. The language of a claim must make it clear what subject matter the claim encompasses to adequately delineate its "metes and bounds". See, e.g., the following decisions: In re Hammack, 427 F 2d. 1378, 1382, 166 USPQ 204, 208 (CCPA 1970); In re Venezia 530 F 2d. 956, 958, 189 USPQ 149, 151 (CCPA 1976); In re Goffe, 526 F 2d. 1393, 1397, 188 USPQ 131, 135 (CCPA 1975); In re Watson, 517 F 2d. 465, 477, 186 USPQ 11, 20 (CCPA 1975); In re Knowlton 481 F 2d. 1357, 1366, 178 USPQ 486, 492 (CCPA 1973). The courts have also indicated that before claimed subject matter can properly be compared to the prior art, it is essential to know what the claims do in fact cover. See, e.g., the following decisions: In re Steele, 305 F 2d. 859, 134 USPQ 292 (CCPA 1962); In re Moore 439 F 2d. 1232, 169 USPQ 236 (CCPA 1969); In re Merat, 519 F 2d. 1390, 186 USPQ 471 (CCPA 1975). Any inquiry concerning this communication or earlier communications from the examiner should be directed to BLAINE LANKFORD whose telephone number is (571)272-0917. The examiner can normally be reached M-Th 8-6:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Louise Humphrey can be reached at 571-272-5543. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. BLAINE LANKFORD Examiner Art Unit 1657 /BLAINE LANKFORD/ Primary Examiner, Art Unit 1657
Read full office action

Prosecution Timeline

Jan 29, 2024
Application Filed
Jun 16, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12680115
BIOGAS COLLECTION APPARATUS AND METHOD OF USE
3y 0m to grant Granted Jul 14, 2026
Patent 12680121
HYALURONIC ACID-PRODUCING RECOMBINANT CELLS
2y 9m to grant Granted Jul 14, 2026
Patent 12667646
ENGINEERING MECHANICALLY FUNCTIONAL HUMAN CARTILAGE AND METHOD OF MAKING SAME
1y 11m to grant Granted Jun 30, 2026
Patent 12661378
METHODS FOR ENHANCING LIFESPAN AND/OR TREATING CELLULAR PROLIFERATIVE DISORDERS BY TRANSPLANTATION
4y 4m to grant Granted Jun 23, 2026
Patent 12656341
PROCESS FOR THE PREPARATION OF LIPIDATED PROTEINACEOUS STRUCTURES
4y 9m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
70%
Grant Probability
99%
With Interview (+30.9%)
3y 8m (~1y 3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 731 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month